A COVID-19 vaccine created by Sanofi and GlaxoSmithKline (GSK) performed well in a clinical trial, the companies said on Feb. 23. The vaccine was 100 percent effective against hospitalization, 75 percent effective against moderate to severe disease, and 58 percent effective against any symptoms, the companies said in a joint statement. The phase 3 trial, which is still ongoing, is analyzing a primary vaccination series, which consists of two doses spaced several weeks apart. The trial includes more than 10,000 participants 18 or older at sides in the United States, Asia, Africa, and Latin America. “We’re very pleased with these data, which confirm our strong science and the benefits of our COVID-19 vaccine,” Thomas Triomphe, Sanofi’s executive vice president, said in a statement. The companies didn’t release data from the trial or another study that is looking at how well a booster dose of the same vaccine does. “In transparency …